NeuroImage

Altered EEG markers of synaptic plasticity in a human model of NMDA receptor deficiency: anti-NMDA receptor encephalitis
--Manuscript Draft--

Manuscript Number:	NIMG-20-1682
Article Type:	Full Length Article
Section/Category:	Anatomy and Physiology
Corresponding Author:	Bigna K. Bölsterli, MD University Children's Hospital Zurich SWITZERLAND
First Author:	Silvano R. Gefferie, MSc.
Order of Authors:	Silvano R. Gefferie, MSc.
	Angelina Maric, PhD
	Hanne Critelli
	Sophie Gueden, MD, PhD
	Gerhard Kurlemann, MD
	Salome Kurth, PhD
	Margherita Nosadini, MD, PhD
	Barbara Plecko, MD
	Maya Ringli, PhD
	Kevin Rostásy, MD
	Stefano Sartori, MD, PhD
	Bernhard Schmitt, MD
	Agnese Suppiej, MD, PhD
	Patrick Van Bogaert, MD, PhD
	Flavia M. Wehrle, PhD
	Reto Huber, PhD
	Bigna K. Bölsterli, MD

Abstract:	Plasticity of synaptic strength and density is a vital mechanism enabling memory consolidation, learning, and neurodevelopment. It is strongly dependent on the intact function of N-methyl-D-aspartate receptors (NMDAR). The importance of NMDAR is further evident as their dysfunction is involved in many diseases such as schizophrenia, Alzheimer's disease, neurodevelopmental disorders, and epilepsies. Synaptic plasticity is thought to be reflected by changes of sleep slow wave slopes across the night, namely higher slopes after wakefulness at the beginning of sleep than after a night of sleep. Hence, a functional NMDAR deficiency should theoretically lead to altered overnight changes of slow wave slopes. Here we investigated whether pediatric patients with anti-NMDAR encephalitis, being a very rare but unique human model of NMDAR deficiency due to autoantibodies against receptor subunits, indeed show alterations in this sleep EEG marker for synaptic plasticity. We retrospectively analyzed 12 whole-night EEGs of 9 patients (age 4.3-20.8 years, 7 females) and compared them to a control group of 45 healthy individuals with the same age distribution. Slow wave slopes were calculated for the first and last hour of non-rapid eye movement (NREM) sleep (factor 'hour') for patients and controls (factor 'group'). There was a significant interaction between 'hour' and 'group' (p = 0.013), with patients showing a smaller overnight decrease of slow wave slopes than controls. Moreover, we found smaller slopes during the first hour in patients (p = 0.022), whereas there was no group difference during the last hour of NREM sleep (p = 0.980). Importantly, the

	distribution of sleep stages was not different between the groups, and in our main analyses of patients without severe disturbance of sleep architecture, neither was the incidence of slow waves. These possible confounders could therefore not account for the differences in the slow wave slope values, which we also saw in the analysis of the whole sample of EEGs.These results suggest that quantitative EEG analysis of slow wave characteristics may reveal impaired synaptic plasticity in patients with anti-NMDAR encephalitis, a human model of functional NMDAR deficiency. Thus, in the future, the changes of sleep slow wave slopes may contribute to the development of electrophysiological biomarkers of functional NMDAR deficiency and synaptic plasticity in general.
Suggested Reviewers:	Lino Nobili Lino.nobili@ospedaleniguarda.it
	Josep Dalmau j.dalmau@clinic.cat
Opposed Reviewers:	

University Children's Hospital Zurich
Department of Neuropediatrics
Steinwiesstrasse 75
8032 Zurich
Switzerland

Dr. med. Bigna K. Bölsterli
Phone ++41 (0)44 266 75 92
Fax   ++41 (0)44 266 71 65
bigna.boelsterli@kispi.uzh.ch

Editor-in-Chief
Dr. Michael Breakspear
Neuroimage
The University of Newcastle
Newcastle
New South Wales
Australia

Zurich, 24th July 2020

Submission of original research paper "*Altered EEG markers of synaptic plasticity in a human model of NMDA receptor deficiency: anti-NMDA receptor encephalitis*"

Dear Dr. Breakspear,

Please find enclosed the manuscript entitled "*Altered EEG markers of synaptic plasticity in a human model of NMDA receptor deficiency: anti-NMDA receptor encephalitis*" by S. R. Gefferie and A. Maric, H. Critelli, S. Gueden, G. Kurlemann, S. Kurth, M. Nosadini, B. Plecko, M. Ringli, K. Rostásy, S. Sartori, B. Schmitt, A. Suppiej, P. Van Bogaert, F. M. Wehrle, R. Huber, and B. K. Bölsterli. We would like this manuscript to be considered for publication as an original research paper in *Neuroimage*.

NMDA receptors (NMDAR) are crucial for synaptic plasticity, which is fundamental to healthy brain functioning. Dysfunction of NMDAR is involved in many disorders, for example schizophrenia, Alzheimer's disease, autism, and epilepsy. Synaptic plasticity, i.e. learning-induced potentiation (long-term potentiation) of synapses during wakefulness and subsequent sleep-dependent depression of synapses (long-term depression), is thought to be reflected by indirect markers that can be assessed in humans, e.g. overnight changes of slow wave slopes in the sleep EEG. In anti-NMDAR encephalitis, autoantibodies lead to a functional NMDAR deficiency. Thus, these patients constitute a human model of NMDAR deficiency.

Here, we present a study in which we assess these EEG markers in a dataset of young anti-NMDAR encephalitis patients. As the disease is rare and whole-night EEGs are performed only seldom in these patients, a collaboration of several centres across Europe was necessary to obtain this unique dataset. The sleep EEG markers for synaptic plasticity were obtained by applying sophisticated quantitative EEG analysis. As hypothesized, we were able to show that these markers, reflecting synaptic plasticity, are indeed altered in patients with NMDAR deficiency when compared to healthy controls of the same age range.

Our data might lay a basis for the future development of electrophysiological biomarkers of NMDAR (dys)function and synaptic plasticity in general. Furthermore, it may also help to interpret alterations observed in such EEG markers.

We believe that the uniqueness and novelty of our manuscript are of high interest to the readership of *Neuroimage*.

We certify that the submission is not under review at any other publication.

With thanks for your kind attention,

Sincerely,

Silvano R. Gefferie, Angelina Maric and Bigna K. Bölsterli

Altered EEG markers of synaptic plasticity in a human model of NMDA

receptor deficiency: anti-NMDA receptor encephalitis

Abbreviated title: altered sleep EEG in anti-NMDAR encephalitis

Silvano R. Gefferie[1]*, Angelina Maric[2]*, Hanne Critelli[1], Sophie Gueden[3], Gerhard

Kurlemann[4], Salome Kurth[5,6], Margherita Nosadini[7], Barbara Plecko[8,1], Maya Ringli[9], Kevin

Rostásy[10], Stefano Sartori[7], Bernhard Schmitt[1], Agnese Suppiej[11,7], Patrick Van Bogaert[3],

Flavia M. Wehrle[12,13], Reto Huber[12,14], Bigna K. Bölsterli[1]

* These authors contributed equally to this work.

Affiliations:

[1] Department of Neuropediatrics, University Children's Hospital Zurich, 8032, Zurich,

Switzerland

[2] Department of Neurology, University Hospital Zurich, University of Zurich, 8091, Zurich,

Switzerland

[3] Service de Pédiatrie, CHU d'Angers, 49933, Angers, France

[4] Children's Hospital Bonifatius Klinik, 49808, Lingen, Germany

[5] Pulmonary Clinic, University Hospital Zurich, 8091, Zurich, Switzerland

[6] Department of Psychology, University of Fribourg, 1700, Fribourg, Switzerland

[7] Pediatric Neurology and Neurophysiology Unit, Department of Women's and Children's

Health, University of Padua, 35122, Padua, Italy

[8] Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical

University of Graz, 8036, Graz, Austria

[9] Department of Neurology, Inselspital, University Hospital Bern, 3010, Bern, Switzerland

[10] Department of Pediatric Neurology, Children's Hospital Datteln, Witten/Herdecke

University, 58448, Datteln/Witten, Germany

[11] Department of Medical Sciences, Pediatric Section, University of Ferrara, 44121, Ferrara,

Italy

[12] Child Development Center, University Children's Hospital Zurich, 8032, Zurich, Switzerland

[13] Department of Neonatology and Pediatric Intensive Care, University Children's Hospital

Zurich, 8032, Zurich, Switzerland

[14] Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital,

University of Zurich, 8091, Zurich, Switzerland

Corresponding author:

Bigna K. Bölsterli

University Children's Hospital Zurich

Department of Neuropediatrics

Steinwiesstrasse 75

8032 Zurich

Switzerland

Phone ++41 (0)44 266 75 92

Fax   ++41 (0)44 266 71 65

bigna.boelsterli@kispi.uzh.ch

Number of pages: 46

Number of figures and tables

Figures: 4

Table: 3

Number of words (including references)

Abstract: 365

Introduction: 603

Discussion: 1567

Declaration of interest:

None

Referee suggestions

Dr. Lino Nobili

Lino.nobili@ospedaleniguarda.it

Prof. Luigi De Gennaro

65 luigi.degennaro@uniroma1.it

66 Dr. Josep Dalmau

67 j.dalmau@clinic.cat

68 Prof. Christian G. Bien

69 christian.bien@mara.de

70 Dr. Albert Compte

71 ACOMPTE@clinic.cat

Abstract

Plasticity of synaptic strength and density is a vital mechanism enabling memory consolidation, learning, and neurodevelopment. It is strongly dependent on the intact function of N-methyl-D-aspartate receptors (NMDAR). The importance of NMDAR is further evident as their dysfunction is involved in many diseases such as schizophrenia, Alzheimer's disease, neurodevelopmental disorders, and epilepsies. Synaptic plasticity is thought to be reflected by changes of sleep slow wave slopes across the night, namely higher slopes after wakefulness at the beginning of sleep than after a night of sleep. Hence, a functional NMDAR deficiency should theoretically lead to altered overnight changes of slow wave slopes. Here we investigated whether pediatric patients with anti-NMDAR encephalitis, being a very rare but unique human model of NMDAR deficiency due to autoantibodies against receptor subunits, indeed show alterations in this sleep EEG marker for synaptic plasticity.

We retrospectively analyzed 12 whole-night EEGs of 9 patients (age 4.3-20.8 years, 7 females) and compared them to a control group of 45 healthy individuals with the same age distribution. Slow wave slopes were calculated for the first and last hour of non-rapid eye movement (NREM) sleep (factor 'hour') for patients and controls (factor 'group'). There was a significant interaction between 'hour' and 'group' ($p = 0.013$), with patients showing a smaller overnight decrease of slow wave slopes than controls. Moreover, we found smaller slopes during the first hour in patients ($p = 0.022$), whereas there was no group difference during the last hour of NREM sleep ($p = 0.980$). Importantly, the distribution of sleep stages was not different between the groups, and in our main analyses of patients without severe disturbance of sleep architecture, neither was the incidence of slow waves. These possible confounders could therefore not account for the differences in the slow wave slope values, which we also saw in the analysis of the whole sample of EEGs. These results suggest that quantitative EEG analysis of slow wave characteristics may reveal impaired synaptic plasticity in patients with anti-NMDAR

encephalitis, a human model of functional NMDAR deficiency. Thus, in the future, the changes

of sleep slow wave slopes may contribute to the development of electrophysiological

biomarkers of functional NMDAR deficiency and synaptic plasticity in general.

Keywords

NMDA receptor, encephalitis, synaptic plasticity, slow waves, sleep homeostasis.

Highlights

• Changes of slow waves in overnight EEGs are thought to reflect synaptic plasticity.

• Synaptic plasticity is strongly dependent on intact NMDAR function.

• Antibody-mediated NMDAR deficiency occurs in patients with anti-NMDAR

encephalitis.

• In this human model of NMDAR deficiency, we found altered slow wave changes.

• Sleep EEG measures may mark NMDAR-related impairments of synaptic plasticity.

Introduction

N-methyl-D-aspartate receptors (NMDAR) are a class of ionotropic glutamate receptors ubiquitously distributed throughout the central nervous system. Due to their importance, it is not surprising that a dysfunction of NMDAR is involved in many diseases such as schizophrenia (Tsai and Coyle, 2002), Alzheimer's disease (Zhang et al., 2016), and epilepsies and neurodevelopmental disorders (Burnashev and Szepetowski, 2015). NMDAR are primarily known for their pivotal role in long-term synaptic plasticity (Escobar et al., 1998; Dupuis et al., 2014). Synaptic plasticity involves behavior-dependent synaptic potentiation during wakefulness, being the basic mechanism of learning, and behavior-independent renormalization of synaptic strength and density during sleep, which has been hypothesized to ensure synaptic homeostasis (Tononi and Cirelli, 2014). Various studies suggested that the processes that underlie synaptic plasticity and homeostasis, i.e. changes in net synaptic strength and synaptic density, are reflected by changes of sleep slow wave (0.5 – 4Hz) characteristics measured in the surface EEG (Esser et al., 2007; Riedner et al., 2007; Vyazovskiy et al., 2009).

Slow waves stem from (near) synchronous activity of large populations of cortical neurons (Esser et al., 2007; Vyazovskiy et al., 2009), which has been related to the strength of synaptic connections (Esser et al., 2007). They are most prominent in non-rapid eye movement (NREM) sleep and can be characterized by various parameters such as incidence, power, amplitude, and slope (Esser et al., 2007). Of these, the slope has been suggested to be the preferred EEG marker for cortical synchrony, being the closest reflection of synaptic strength (Riedner et al., 2007; Vyazovskiy et al., 2009). Accordingly, changes of slow wave slopes from the first hour (FH) to the last hour (LH) of NREM sleep have been used to indirectly measure synaptic plasticity (Bölsterli et al., 2011; Fattinger et al., 2015). This typically results in steeper slopes of slow waves at the beginning of sleep because of synaptic potentiation during previous wakefulness and a homeostatic decrease of slow wave slopes across the night (Riedner et al., 2007).

The analysis of sleep slow waves has indicated that synaptic plasticity may be challenged in

various conditions, including major depressive disorder (Armitage et al., 2000), encephalopathy

with status epilepticus during sleep (ESES) (Bölsterli et al., 2011) and infantile spasms

(Fattinger et al., 2015). Since synaptic plasticity requires properly functioning NMDAR, a

dysfunction would expectably result in altered changes of slow wave characteristics during a

night's sleep. Such a functional NMDAR deficiency may emerge in different ways, for example

by interventions such as gene editing and receptor antagonism (Campbell and Feinberg, 1996;

Miyamoto et al., 2003), or by antibodies against the NMDAR as seen in anti-NMDAR

encephalitis.

Anti-NMDAR encephalitis is a well-recognized but very rare disease due to autoantibodies

against the NR1-subunit of NMDAR (Dalmau et al., 2007, 2008). Anti-NMDAR antibodies

disturb receptor functionality by cross-linking them, which leads to their internalization into

neurons, causing a functional NMDAR deficiency (Hughes et al., 2010). Accordingly, such

patients constitute a human model of NMDAR deficiency, which suggests that the receptors'

role in synaptic plasticity is impaired.

In this retrospective, multicenter, case-control study, we hypothesized that the changes of slow

wave slopes across the night in pediatric patients with anti-NMDAR encephalitis, representing

a human model of NMDAR deficiency, are altered, i.e. show diminished patterns of change.

To this end, we compared changes of slow wave slopes from the FH to the LH of NREM sleep

between patients and healthy controls of corresponding age. To rule out that differences in other

sleep variables such as sleep stage distributions or the mere counts of slow waves would drive

group differences in slow wave slopes, we additionally compared these variables between the

groups.

Materials and Methods

Participants

Patients diagnosed with anti-NMDAR encephalitis were provided by the Department of Neuropediatrics, University Children's Hospital Zurich (Switzerland); the Department for Women's and Children's Health, Pediatric Neurology and Neurophysiology Unit, University of Padua (Italy); the Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke (Germany); the University Hospital Muenster, Westfalian Wilhelms University (Germany); and the Service de Pédiatrie, CHU d'Angers (France). Twenty-one EEGs from thirteen patients (ten females) recorded between 2008 and 2019 were available. We included patients that met all the following inclusion criteria:

- Detection of anti-NMDAR antibodies in serum and/or cerebrospinal fluid
- At least one whole-night sleep-EEG recording of sufficing data quality and without highly pathological changes that allowed scoring of sleep stages
- Under the age of 21 years at the time of EEG recording

Nine EEGs from nine patients had to be excluded because of the following reasons (number between parentheses): inability to score sleep stages, for example due to excessive artifacts (6); the EEG not being a whole-night registration (1); incompleteness of the EEG (1); and a lack of sleep during the recording (1). Consequently, we included 12 whole-night EEGs from 9 patients (7 females, age 4.3 – 20.8 years, mean 12.3 years) at different stages of their disease. Clinical and electrographic characteristics of included patients are provided in Table 1 and Supplementary Table 1.

[Insert Table 1]

As representative references for each patient, we included five healthy controls with one whole-night EEG recording from studies conducted between 2008 and 2019 by the research group of

Reto Huber from the University Children's Hospital Zurich (Kurth et al., 2012; Wehrle et al.,

2017; Volk et al., 2019; unpublished observations). Age-wise, these controls differed at most

1.1 years from the corresponding patient, resulting in an age distribution in controls (age 4.2 -

21.4 years, mean 12.4 years) that was comparable to that in patients. This procedure was carried

out to avoid that age-related differences in sleep slow wave characteristics could eventually

drive differences between patients and controls (Kurth et al., 2010b). Moreover, the sex of

controls was matched for all but one patient. For this young male patient (7.4 years), we

included three male and two female controls, as no more data of male controls in that age range

were available. Importantly, sex influences on sleep parameters are thought to be minimal

before puberty (Knutson, 2005; Johnson et al., 2006).

This study was performed at the University Children's Hospital Zurich. All participants or their

legal representatives gave written informed consent for the use of their non-identifiable, health-

related data for research purposes – acknowledged by their local authorities. Ethical approval

was provided by the ethical committee of the canton of Zurich (BASEC Nr. 2016-02154).

EEG recordings

The recordings from the patients in Zurich were performed using a Neurofile XP EEG System

(Natus Europe GmbH, Munich, Germany), with 19 electrodes according to the international 10-

20 system. Their EEG data were sampled at 256 Hz, and analogously (band-pass 0.016 – 300

Hz) and digitally (band-pass 0.53 – 70 Hz) filtered. At the Children's Hospital Datteln, a

Neurofax EEG-9210 System (Berger Medizintechnik GmbH, Gleisdorf, Österreich) was used.

The signals were sampled at 200 Hz and digitally band-pass filtered (0.53 – 70 Hz). At the

Pediatric Clinical Hospital of Padua, EEG data were acquired with Galileo NT Software (EB

Neuro S.p.A, Florence, Italy), sampled at 256 Hz, and analogue wide-band filtered (0 – 20 kHz).

The EEGs from the University Hospital Angers were registered with a Deltamed Brainbox-

1042 EEG amplifier (Natus Europe GmbH, Munich, Germany), sampled at 256 Hz, and

digitally high- and low-pass filtered at 0.17 Hz and 100 Hz, respectively. The EEGs from

patients in Angers, Datteln and Padua had at least eight EEG electrodes placed on 10-20-

positions. The six common electrodes among all EEGs were O1, O2, Fp1, Fp2 and temporal

electrodes (either T3 and T4, or T5 and T6). The EEGs from Münster were excluded due to

excessive artifacts.

To avoid inter-rater variability, all sleep stage scoring for patients was done by a single, trained

EEG technician (H.C.) according to the standard criteria from the American Association of

Sleep Medicine (AASM) (Iber et al., 2007), applied to 20-sec epochs.

EEGs for controls were recorded using a 128-channels high-density EEG system (Electrical

Geodesics, Inc.; Sensor Net for long-term monitoring). The data were sampled at 500 Hz

(analogously filtered between 0.01 and 200 Hz) and then digitally band-pass filtered (0.5 – 50

Hz). Scoring was done by investigators of the original studies (Kurth et al., 2012; Wehrle et al.,

2017; Volk et al., 2019; unpublished observations) according to the guidelines from the AASM

(Iber et al., 2007), applied to 20-sec epochs.

EEG analyzes

After acquisition and scoring of all patient and control EEG recordings, data were further

analyzed in MATLAB R2017b (The MathWorks, Inc., Natick, MA). All EEGs were

downsampled to 128 Hz, after which semi-automatic artifact detection was performed as

described in (Huber et al., 2000). Channels containing artifacts in more than 5% of all 20-sec

epochs were excluded from further analysis. The recordings were then re-referenced to the

average of O1 and O2, as these electrodes were available for all EEG recordings and slow wave

activity (SWA) is typically most prominent in anterior regions in the age range of the

investigated participants (Werth et al., 1997; Finelli et al., 2001; Kurth et al., 2010b, 2012).

A slow wave detection algorithm based on the method first described by (Riedner et al., 2007)

was used for the detection of slow waves. EEG signals from all derivations were band-pass

filtered (0.5 – 4.0 Hz, stopband 0.1 and 10 Hz) using a Chebyshev Type II filter (MATLAB,

The MathWorks Inc, Natick, MA). Maximal attenuation in the passband was 3 dB and minimal

attenuation in the stopband was 10 dB. Negative deflections of the EEG signal were depicted

as 'negative half-waves'. Negative half-waves with an interval of 0.25 to 1.0 seconds between

the zero-crossings, i.e. wave frequency 0.5 – 2 Hz, were considered slow waves. These were

detected in all artifact-free epochs of NREM sleep. Then, slow waves occurring in the first and

last hour of NREM sleep were selected for slope analyzes. Slopes of slow waves were

calculated by dividing the amplitude of the most negative deflection by the interval until the

next zero-crossing (Kurth et al., 2010a). Subsequently, they were corrected for amplitude as

described in earlier work by calculating their value at the amplitude of 75 µV (further termed

'slope'), because amplitude and slope are inherently correlated (Bölsterli et al., 2011, 2017;

Bölsterli Heinzle et al., 2014). Furthermore, numbers of detected slow waves were determined

for the FH of NREM sleep, LH of NREM sleep, and for the total time spent in NREM sleep,

i.e. from the first to the last EEG epoch scored as NREM sleep. Mean slopes and numbers of

detected slow waves were calculated for electrodes Fp1, Fp2, T3 or T5, and T4 or T6

(dependent on availability). In a second step, these values were averaged across these

electrodes. The absolute and relative (i.e. with respect to the total sleep time) durations of sleep

stages were calculated based on sleep stage-scored EEG epochs.

Statistical analysis

Statistics were conducted with IBM SPSS Statistics (IBM Corp. Released 2017. IBM SPSS

Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). The one patient (#5) in whom

the EEG was recorded clearly after clinical recovery, i.e. 4 years after the last manifestation of

active disease, was excluded from quantitative statistical analysis. The corresponding slow

wave analysis results were merely described qualitatively. In the statistical analysis, we

included only those patient EEG recordings for which clinicians evaluated the hypnograms as

normal, to eliminate influences of pathological sleep architecture on potential group differences

in slow wave characteristics. This left 6 patients with 8 EEGs for statistical comparison to 30

controls. For each patient with two consecutive EEGs (designated EEG 'A' and 'B',

respectively), ages at time of recording (2 to 10 weeks apart) and EEG analysis outcomes were

averaged before any further analysis. Subsequently, statistical analysis was repeated, including

also the patients and EEGs that showed pathologically fragmented sleep as described above.

The results thereof are only reported in detail if they deviated from those previously reported.

For the analysis of slow wave slope variables between the two groups of participants, a 2x2

mixed ANOVA was performed with the within-subject factor 'hour' (FH vs. LH) and the

between-subject factor 'group' (patients vs. controls). Standardized residuals were checked for

the assumption of normal distribution (Shapiro-Wilk test). Following a significant interaction,

we performed a priori defined post hoc tests, i.e. two-tailed independent samples t-tests,

comparing slopes during the FH and the LH between patients and controls, with Bonferroni

correction for multiple comparisons (realized by multiplying p-values by the number of post

hoc comparisons). In case residuals of the mixed ANOVA were deviating from a normal

distribution, pairwise non-parametric procedures (two-tailed Mann-Whitney U-tests) with

Bonferroni correction for multiple comparisons were directly performed instead, comparing the

slope changes between the FH and the LH, slopes during the FH, and slopes during the LH

between patients and controls.

We compared further sleep EEG characteristics, i.e. numbers of detected slow waves and

distribution of sleep stage distribution, directly between the groups. As some of the variables

were not normally distributed, we applied non-parametric testing (two-tailed Mann-Whitney

U-test) to all these variables.

Pearson correlation coefficients were calculated to assess the significance of associations

between variables if residuals were normally distributed. Spearman correlation coefficients are

reported otherwise. The threshold for significance for statistical analyzes was set at $p < 0.05$.

Data and code availability

MATLAB scripts used for the analyses in this study are provided by the corresponding author

upon reasonable request.

Results

Changes of slow wave slopes across the night

In the analysis of slopes of slow waves during the FH and LH of NREM sleep in patients (#1 (B), #2, #4, #6, #7, and #9) and controls, we found a significant main effect for both hour ($F(1, 34) = 33.31$, $p < 0.001$, ANOVA) and group ($F(1, 34) = 4.65$, $p = 0.038$, ANOVA). This signifies that slopes were, in general, higher during the FH than during the LH (+54.02 ± 9.36 µV/s, difference of means ± standard error of difference, based on estimated marginal means) and overall higher in controls compared to patients (+43.02 ± 19.95 µV/s). Importantly, there was a significant interaction between hour and group ($F(1, 34) = 6.91$, $p = 0.013$, ANOVA). Namely, the decrease of the slope from the FH to the LH was significantly more pronounced in controls compared to patients (-49.21 ± 16.15 µV/s, Fig. 1). Post hoc tests revealed that controls showed significantly steeper slopes than patients during the FH (+67.62 ± 21.38 µV/s, $t(34) = 2.598$, $p = 0.022$, independent samples t-test), whereas there was no significant difference between the groups for slopes during the LH (18.41 ± 25.24 µV/s, $t(34) = 1.074$, $p = 0.980$, independent samples t-test, Fig. 1). Besides, while controls demonstrated a strong correlation between the slope during the FH of NREM sleep and the change of the slope across the night ($r(28) = -0.845$, $p < 0.001$, Pearson correlation coefficient, Fig. 2), there was no equivalent finding for patients with anti-NMDAR encephalitis ($r(4) = 0.125$, $p = 0.814$, Pearson correlation coefficient, Fig. 2). This means for control participants that, the steeper the slope was in the FH, the more it decreased towards the LH. In contrast, this relationship could not be confirmed in patients.

Results were comparable when we included the three patient EEGs with abnormal sleep architecture (#1 (A), #3, and #8) in the analysis (data not shown).

[Insert Figure 1]

312   [Insert Figure 2]

Changes in individual participants

All controls consistently showed a decrease in the slope from the FH to the LH of NREM sleep

(range -198.94 to -0.79 µV/s), whereas this was less consistent in patients (range -64.39 to 33.97

µV/s). Most of the latter showed a decrease (#1, #2, #3, #5, #6, and #9), but several also showed

an increase (#4, #7, and #8), see Table 2 and Fig. 3. The overnight change of the slope in patient

#5 (-31.57 µV/s), whose EEG was recorded 4 years after a relapse of anti-NMDAR encephalitis,

was within the relatively small range of corresponding control values (-25.43 to -55.96 µV/s)

(Table 2, Fig. 3). Similarly, this patient's slope values during the FH and LH of NREM sleep

(363.63 µV/s and 332.05 µV/s, respectively) were either within or close to the values from the

corresponding controls (361.78 to 401.19 µV/s and 333.15 to 347.60 µV/s, respectively).

[Insert Table 2]

[Insert Figure 3]

Further sleep EEG characteristics

Numbers of detected slow waves during the FH of NREM, the LH of NREM, and all NREM

of the sleep period were not different between the groups (Table 3). Repeating the analysis after

including the three patient recordings with severe sleep disturbance yielded a significantly

lower number of slow waves in patients (median 1584.56, IQR 1074.69, $U = 78.00$, $p = 0.022$,

Mann-Whitney U-test) than in controls (median 2261.25, IQR 809.19) during the FH of NREM

sleep. Yet, counts of slow waves were not different during the LH or all NREM sleep in the

sleep period (data not shown).

In addition, patients did not significantly differ from controls in the length of any of the sleep-

wake stages, apart from a longer sleep duration (time from falling asleep to waking up) during

the EEG recording (difference of medians +1.73 hours, $U = 15.00$, $p = 0.001$, Mann-Whitney

U-test) (Table 3). Comparable statistical outcomes were found when the three patient EEGs

with disturbance of sleep architecture were included for analysis (data not shown).

338   [Insert Table 3]

339   **Participants' ages and changes of slopes across the night**

340   Healthy individuals showed smaller overnight decreases of slow wave slopes with increasing

341   age (Spearman's rho(28) = 0.724, $p < 0.001$, Fig. 4). Contrastingly, such an age-related effect

342   was not evident in patients (Spearman's rho(4) = 0.086, $p = 0.872$). Results were comparable

343   when the three initially excluded patient EEGs were added to the analysis (Fig. 4).

344   [Insert Figure 4]

Discussion

In this study, we hypothesized that changes of slow wave slopes from the FH to the LH of NREM sleep, an indirect measure of synaptic plasticity (Riedner et al., 2007; Vyazovskiy et al., 2009), are altered in a human model of NMDAR deficiency caused by anti-NMDAR antibodies, i.e. patients with anti-NMDAR encephalitis. Results confirmed that the overnight decrease of the slope is significantly smaller for patients than for healthy controls, accompanied by significantly smaller slopes during the FH of NREM sleep. Contrastingly, the slope during the LH of NREM sleep does not significantly differ between patients and controls. These results are in support of our hypothesis and, therefore, suggest that the analyzed sleep EEG markers for synaptic plasticity are sensitive to an NMDAR deficiency as evident in anti-NMDAR encephalitis. We conclude that synaptic plasticity seems altered in this human model of NMDAR deficiency.

Various studies have proposed the functional involvement of cortical NMDAR in slow wave sleep (NREM stage 3) (Armstrong-James and Fox, 1988; Bazhenov et al., 2002; Duncan et al., 2013). Yet, disruption of NMDAR function in animals revealed that these receptors are additionally engaged in changes of EEG slow waves following synaptic potentiation during wakefulness (Campbell and Feinberg, 1996; Miyamoto et al., 2003). Electro-encephalographic abnormalities have also been investigated in anti-NMDAR encephalitis patients, i.e. human models of NMDAR deficiency (Gitiaux et al., 2013; Nosadini et al., 2015; Benjumea-Cuartas et al., 2017). However, to the best of our knowledge, this is the first study comparing slow wave characteristics during NREM sleep between patients with anti-NMDAR encephalitis and healthy individuals.

The synaptic homeostasis hypothesis may contribute to the understanding of the observations in patients with functional NMDAR deficiency. It states that the degree of net synaptic

downscaling during sleep is closely tied to the net increase in synaptic strength during prior

wakefulness (Tononi and Cirelli, 2014). Synaptic strengthening during wakefulness is the result

of long-term potentiation (LTP) of cortical circuits, which is assumed to be the primary

mechanism of learning (Dupuis et al., 2014). Numerous studies suggested that the synaptic

strength of cortical connections is reflected by the slope of slow waves (Esser et al., 2007;

Riedner et al., 2007; Vyazovskiy et al., 2009). As NMDAR are crucial for the induction of LTP

(Collingridge and Bliss, 1987), the smaller slopes during the FH of NREM sleep in patients

could indicate less LTP during wakefulness because of NMDAR deficiency.

However, NMDAR also play a role in promoting long-term depression (LTD) of synaptic

networks (Nabavi et al., 2013; González-Rueda et al., 2018). LTD is predominant during sleep,

causing a net decrease of synaptic strength (Tononi and Cirelli, 2014). The smaller slope

decrease in patients with NMDAR deficiency may, therefore, indicate that also LTD is

impaired. As patients were at different stages of their disease, different degrees of NMDAR

deficiency and thus alterations in synaptic plasticity were expected, which is supported by the

high variability of overnight changes of slopes in patients (Table 2, Fig. 3). Moreover, to

achieve homeostasis of synaptic strength, we would expect these overnight changes of slopes

to relate to the level at the beginning of sleep resulting from previous wakefulness. The lack of

a correlation between slopes during the FH of NREM sleep and their change during sleep in

patients (Fig. 2) implies that the homeostatic regulation of slow waves is disrupted. This

indicates a dysfunction of synaptic homeostasis independent of smaller slopes at the beginning

of sleep.

Functional NMDAR are considered crucial in the maintenance of normal sleep patterns (Vataev

et al., 2014; Tomita et al., 2015). Aberrant sleep patterns, observed in patients with anti-

NMDAR encephalitis (Florance et al., 2009; Irani et al., 2010; Gitiaux et al., 2013), may

theoretically influence the overnight changes of slow waves. To minimize such a confounding

effect, only patient EEGs with visually normal appearing hypnograms were included in the

main statistical analysis. Besides longer total sleep periods in patients, neither durations and

proportions of sleep stages, nor the numbers of detected slow waves differed between patients

and controls (Table 3). Additionally, by including controls with similar age as patients, we

prevented that age-related differences in overnight slope decrease – as confirmed to exist in

healthy subjects (Fig. 4) – would have driven the outcomes. Therefore, the altered slow wave

slope values in our patients are likely to be the result of factors beyond altered sleep architecture

and age.

The majority of patients in this study were female (7/9), corresponding with the fact that females

are predisposed for the development of anti-NMDAR encephalitis (Suh-Lailam et al., 2013).

One of them, patient #5, was measured more than 5 years after diagnosis and about 4 years after

a relapse of the disease. She had no clinical sequelae. Clinical recovery from anti-NMDAR

encephalitis occurs due to a decrease of anti-NMDAR antibodies, leading to the recuperation

of NMDAR function (Hughes et al., 2010). Recuperated NMDAR function could be

explanatory for results from patient #5, being within or close to the narrow range of values of

corresponding controls (Fig. 3). However, since we do not have an EEG during active disease,

it remains unknown whether slow wave slope variables were altered at that time. Reversibility

of pathologically altered overnight changes of slow wave slopes has been shown in ESES

(Bölsterli et al., 2017), a disease that has been linked to a genetically determined gain of

NMDAR function (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013).

This study also has limitations. One of them is certainly the small number of patients included

(n = 9). However, given the rarity of pediatric anti-NMDAR encephalitis (Leypoldt et al., 2013)

and the scarcity of whole-night EEGs in its patients, we believe the size of our dataset is

reasonably large. In particular, the large control group with the same age distribution rendered

it unlikely that differences arose from the selected controls since it accounted for the variance

that exists between individuals in a specific age range. Additionally, 9/21 EEGs were not

analyzable due to artifacts and severely altered background activity preventing sleep stage

scoring. Patients in the acute phase of the disease are frequently agitated and suffer hyper-motor

movement disorders; both reasons for EEG artifacts. These issues may have introduced a

selection bias towards patients less affected at the time of the EEG. This possible bias would

reduce differences compared to healthy controls. Importantly, despite the small sample size and

EEGs of rather less affected individuals, we nonetheless demonstrate significant group effects.

A possible confounder could have been that most of the patients with active disease underwent

drug treatment at the time of the EEG registration. This included corticosteroids and a variety

of anti-seizure agents (Supplementary Table 1). Various substances have been suggested to

alter slow wave sleep in different directions (Holsboer et al., 1988; Legros and Bazil, 2003). In

earlier studies of our group, we showed that corticosteroids reduce the slope of slow waves in

infants with infantile spasms. However, the overnight change of slope was not investigated

(Fattinger et al., 2015). Due to the small sample size in this study, the effect of corticosteroids

could only be analyzed qualitatively. Slope values during the FH and LH, as well as overnight

changes of the slope in patients on corticosteroids, were below, within, and above the levels of

controls (Fig. 3). Hence, a systematic influence of corticosteroid treatment on how slope values

differed from the corresponding controls is highly unlikely. Additionally, the wide variety of

anti-seizure drugs hindered grouping of patients to accurately estimate their effects.

Consequently, we cannot exclude an influence of anti-seizure drug treatments on our results,

even though a systematic effect is improbable because of the large variability in treatments.

Despite these limitations, we believe that our study is unique as it contains a group of young

patients with a very rare, yet well-defined disease (by the occurrence of clinical symptoms and

anti-NMDAR antibodies), which we compared to a large healthy control group of the same age

and (nearly) same sex distribution.

Future perspectives related to this first study on overnight changes of slow wave slopes in a

human model of NMDAR deficiency would be to conduct prospective and ideally longitudinal

multicenter studies with standardized data acquisition (clinical, laboratory, imaging and EEG

data) in larger samples of patients with anti-NMDAR encephalitis. Such studies could clarify

whether dysregulated changes of slow wave slopes across the night can account for clinical

symptoms and if recovery of overnight changes of the slopes is accompanied by a clinical

recovery in patients. Besides, more direct markers of functional NMDAR, for example levels

of autoantibodies against NMDAR, could be related to the EEG markers of synaptic plasticity.

This would be a next step towards a novel, clinically applicable, electrophysiological biomarker

for pathologies of synaptic plasticity.

In conclusion, patients with anti-NMDAR encephalitis compared to controls show a smaller

decrease of slow wave slopes over the course of the night and smaller slopes at the beginning

of the night. As these patients are known to have reduced functional NMDAR and as changes

in slow wave slopes have been suggested to reflect synaptic plasticity, our results support the

presumption that synaptic plasticity during sleep and wakefulness, including synaptic

homeostasis, is hampered due to functional NMDAR deficiency. In future, the slope of slow

waves might be used as an instrument for recognition of altered neuronal plasticity, for example

due to altered NMDAR function in diseases and physiological situations such as learning or

normal development.

Acknowledgements

This work was supported by radiz - Rare Disease Initiative Zurich (to S.R.G.), the Swiss

National Science Foundation (PCEFP1-181279) (to S.K.), the Swiss National Science

Foundation (320030-179443 and 320030-153387) (to R.H.), the Clinical Research Priority

Program "Sleep and Health" of the University of Zurich (to R.H.), the Anna Müller Grocholski

foundation and the EMDO foundation.

We thank Jakob Heinzle for his suggestions and inputs regarding the statistical approach.

References

Armitage R, Hoffmann R, Trivedi M, Rush AJ (2000) Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. Psychiatry Res 95:201–213.

Armstrong-James M, Fox K (1988) Evidence for a specific role for cortical NMDA receptors in slow-wave sleep. Brain Res 451:189–196.

Bazhenov M, Timofeev I, Steriade M, Sejnowski TJ (2002) Model of thalamocortical slow-wave sleep oscillations and transitions to activated states. J Neurosci 22:8691–8704.

Benjumea-Cuartas V, Eisermann M, Simonnet H, Hully M, Nabbout R, Desguerre I, Kaminska A (2017) Unilateral predominance of abnormal movements: A characteristic feature of the pediatric anti-NMDA receptor encephalitis? Epilepsy Behav Case Reports 7:42–44.

Bölsterli BK, Gardella E, Pavlidis E, Wehrle FM, Tassinari CA, Huber R, Rubboli G (2017) Remission of encephalopathy with status epilepticus (ESES) during sleep renormalizes regulation of slow wave sleep. Epilepsia 58:1892–1901.

Bölsterli BK, Schmitt B, Bast T, Critelli H, Heinzle J, Jenni OG, Huber R (2011) Impaired slow wave sleep downscaling in encephalopathy with status epilepticus during sleep (ESES). Clin Neurophysiol 122:1779–1787.

Bölsterli Heinzle BK, Fattinger S, Kurth S, Lebourgeois MK, Ringli M, Bast T, Critelli H, Schmitt B, Huber R (2014) Spike wave location and density disturb sleep slow waves in patients with CSWS (continuous spike waves during sleep). Epilepsia 55:584–591.

Burnashev N, Szepetowski P (2015) NMDA receptor subunit mutations in neurodevelopmental disorders. Curr Opin Pharmacol 20:73–82.

Campbell IG, Feinberg I (1996) NREM delta stimulation following MK-801 is a response of sleep systems. J Neurophysiol 76:3714–3720.

Carvill GL et al. (2013) GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet

45:1073–1076 Available at: https://doi.org/10.1038/ng.2727.

Collingridge GL, Bliss TVP (1987) NMDA receptors - their role in long-term potentiation. Trends

Neurosci 10:288–293.

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-

Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the

effects of antibodies. Lancet Neurol 7:1091–1098.

Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R,

King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic

Anti–N-methyl-D-aspartate Receptor Encephalitis Associated with Ovarian Teratoma. Ann

Neurol 61:25–36.

Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK,

Tononi G, Zarate CA (2013) Concomitant BDNF and sleep slow wave changes indicate

ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16:301–

311.

Dupuis JP, Ladépêche L, Seth H, Bard L, Varela J, Mikasova L, Bouchet D, Rogemond V, Honnorat

J, Hanse E, Groc L (2014) Surface dynamics of GluN2B‐ NMDA receptors controls plasticity of

maturing glutamate synapses. EMBO J 33:842–861.

Escobar ML, Chao V, Bermúdez-Rattoni F (1998) In vivo long-term potentiation in the insular cortex:

NMDA receptor dependence. Brain Res 779:314–319.

Esser SK, Hill SL, Tononi G (2007) Sleep homeostasis and cortical synchronization: I. Modeling the

effects of synaptic strength on sleep slow waves. Sleep 30:1617–1630.

Fattinger S, Schmitt B, Bölsterli Heinzle BK, Critelli H, Jenni OG, Huber R (2015) Impaired slow

wave sleep downscaling in patients with infantile spasms. Eur J Paediatr Neurol 19:134–142.

Finelli LA, Borbely AA, Achermann P (2001) Functional topography of the human nonREM sleep

electroencephalogram. Eur J Neurosci 13:2282–2290.

Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N,

Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J (2009) Anti-N-Methyl-D-

Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents. Ann Neurol 66:11–18.

Gitiaux C, Simonnet H, Eisermann M, Leunen D, Dulac O, Nabbout R, Chevignard M, Honnorat JÔ,

Gataullina S, Musset L, Scalais E, Gauthier A, Hully M, Boddaert N, Kuchenbuch M, Desguerre

I, Kaminska A (2013) Early electro-clinical features may contribute to diagnosis of the anti-

NMDA receptor encephalitis in children. Clin Neurophysiol 124:2354–2361.

González-Rueda A, Pedrosa V, Feord RC, Clopath C, Paulsen O (2018) Activity-Dependent

Downscaling of Subthreshold Synaptic Inputs during Slow-Wave-Sleep-like Activity In Vivo.

Neuron 97:1244-1252.e1-e5.

Holsboer F, von Bardeleben U, Steiger A (1988) Effects of Intravenous Corticotropin-Releasing

Hormone upon Sleep-Related Growth Hormone Surge and Sleep EEG in Man.

Neuroendocrinology 48:32–38.

Huber R, Graf T, Cote KA, Wittmann L, Gallmann E, Matter D, Schuderer J, Kuster N, Borbely AA,

Achermann P (2000) Exposure to pulsed high-frequency electromagnetic field during waking

affects human sleep EEG. Neuroreport 11:3321–3325.

Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J,

Balice-Gordon RJ (2010) Cellular and Synaptic Mechanisms of Anti-NMDA Receptor

Encephalitis. J Neurosci 30:5866–5875.

Iber C, Ancoli-Israel S, Chesson AL, Quan S (2007) The AASM Manual for the Scoring of Sleep and

Associated Events: Rules, Terminology and Technical Specifications. Am Acad Sleep Med.

Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM,

Beeson D, Lang B, Bien CG, Vincent A (2010) N-methyl-d-aspartate antibody encephalitis:

temporal progression of clinical and paraclinical observations in a predominantly non-

paraneoplastic disorder of both sexes. Brain 133:1655–1667.

Johnson EO, Roth T, Schultz L, Breslau N (2006) Epidemiology of DSM-IV insomnia in adolescence:

lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 117:e247–e256.

Knutson KL (2005) The association between pubertal status and sleep duration and quality among a

nationally representative sample of U. S. adolescents. Am J Hum Biol 17:418–424.

Kurth S, Jenni OG, Riedner BA, Tononi G, Carskadon MA, Huber R (2010a) Characteristics of sleep

slow waves in children and adolescents. Sleep 33:475–480.

Kurth S, Ringli M, Geiger A, LeBourgeois M, Jenni OG, Huber R (2010b) Mapping of Cortical

Activity in the First Two Decades of Life: A High-Density Sleep Electroencephalogram Study. J

Neurosci 30:13211–13219.

Kurth S, Ringli M, Lebourgeois MK, Geiger A, Buchmann A, Jenni OG, Huber R (2012) Mapping the

electrophysiological marker of sleep depth reveals skill maturation in children and adolescents.

Neuroimage 63:959–965.

Legros B, Bazil CW (2003) Effects of antiepileptic drugs on sleep architecture: a pilot study. Sleep

Med 4:51–55.

Lemke JR et al. (2013) Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes.

Nat Genet 45:1067–1072.

Lesca G et al. (2013) GRIN2A mutations in acquired epileptic aphasia and related childhood focal

epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 45:1061–

1066.

Leypoldt F, Wandinger K-P, Bien CG, Dalmau J (2013) Autoimmune Encephalitis. Eur Neurol Rev

8:31–37.

Miyamoto H, Katagiri H, Hensch T (2003) Experience-dependent slow-wave sleep development. Nat

Neurosci 6:553–554.

Nabavi S, Kessels HW, Alfonso S, Aow J, Fox R, Malinow R (2013) Metabotropic NMDA receptor

function is required for NMDA receptor-dependent long-term depression. Proc Natl Acad Sci

110:4027–4032.

Nosadini M, Boniver C, Zuliani L, de Palma L, Cainelli E, Battistella PA, Toldo I, Suppiej A, Sartori

S (2015) Longitudinal electroencephalographic (EEG) findings in pediatric anti-N-methyl-D-

aspartate (anti-NMDA) receptor encephalitis: the Padua experience. J Child Neurol 30:238–245.

Riedner BA, Vyazovskiy V V, Huber R, Massimini M, Esser S, Murphy M, Tononi G (2007) Sleep

Homeostasis and Cortical Synchronization: III. A High-Density EEG Study of Sleep Slow

Waves in Humans. Sleep 30:1643–1657.

Suh-Lailam BB, Haven TR, Copple SS, Knapp D, Jaskowski TD, Tebo AE (2013) Anti-NMDA-

receptor antibody encephalitis: Performance evaluation and laboratory experience with the anti-

NMDA-receptor IgG assay. Clin Chim Acta 421:1–6.

Tomita J, Ueno T, Mitsuyoshi M, Kume S, Kume K (2015) The NMDA Receptor Promotes Sleep in

the Fruit Fly, Drosophila melanogaster. PLoS One 10:e0128101.

Tononi G, Cirelli C (2014) Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis

to Memory Consolidation and Integration. Neuron 81:12–34.

Tsai G, Coyle JT (2002) Glutamatergic Mechanisms in Schizophrenia. Annu Rev Pharmacol Toxicol

42:165–179.

Vataev SI, Oganesyan GA, Gmiro VE, Lukomskaya NY, Magazanik LG (2014) Effects of Ionotropic

Glutamate Receptor Channel Blockers on the Organization of Sleep in Rats. Neurosci Behav

Physiol 44:365–370.

Volk C, Jaramillo V, Studler M, Furrer M, Tuura RLO, Huber R (2019) Diurnal changes in human

brain glutamate + glutamine levels in the course of development and their relationship to sleep.

Neuroimage 196:269–275.

Vyazovskiy V V, Olcese U, Lazimy YM, Faraguna U, Esser SK, Williams JC, Cirelli C, Tononi G

(2009) Cortical firing and sleep homeostasis. Neuron 63:865–878.

Wehrle FM, Latal B, O'Gorman RL, Hagmann CF, Huber R (2017) Sleep EEG maps the functional

neuroanatomy of executive processes in adolescents born very preterm. Cortex 86:11–21.

Werth E, Achermann P, Borbély A (1997) Fronto-ocipital EEG power gradients in human sleep. J

Sleep Res 6:102–112.

Zhang Y, Li P, Feng J, Wu M (2016) Dysfunction of NMDA receptors in Alzheimer's disease. Neurol

Sci 37:1039–1047.

Figures

Figure 1

Slow wave slope for the first and last hour of non-rapid eye movement (NREM) sleep. Group mean
values are provided for patients (black diamonds and dashed line) and control participants (grey circles
and solid line). Error bars represent the standard error of the mean. The asterisk (*) indicates a significant
interaction effect for 'hour' and 'group', i.e. the overnight (first hour to last hour of NREM sleep) change
of the slow wave slope is different in patients and controls. Post hoc analyzes revealed a significant
group difference for the first hour (marked by a black, solid triangle; $p < 0.05$; two-tailed independent
samples t-test; Bonferroni corrected by multiplying the p-value by the number of post hoc tests), but not
for the last hour of NREM sleep.

612 **Figure 2**

614 Slow wave slope during the first hour of non-rapid eye movement (NREM) sleep and the slow wave

615 slope change across the night. Values are provided for patients (black diamonds) and control participants

616 (grey circles).

Figure 3

Slow wave slope variables for individual patients and corresponding controls. Values are shown for the

change of the slow wave slope across the night (panel A), the slow wave slope during the first hour of

non-rapid eye movement (NREM) sleep (panel B), and the slow wave slope during the last hour of

NREM sleep (panel C). Patients (black diamonds) and controls (grey circles) that corresponded to them,

i.e. not more than 1.1 years different in age, are ordered according to their ages, increasing from left to

right. Patient #5, indicated with an asterisk (*), was measured in remission and was therefore not

included in the analysis of patients during active anti-NMDAR encephalitis (see Materials and Methods

for details).

Figure 4

Participant's age at the time of the EEG recording and change of the slope across the night. Patient

values are shown by black diamonds, whereas values from control participants are represented by grey

circles. Circumflexes (^) denote EEGs of which hypnograms were determined by a clinician to

demonstrate abnormal sleep architecture (see Materials and Methods for a specification). As the

residuals of the variables plotted were not normally distributed, Spearman correlation coefficients were

calculated. In the figure, the linear regression line for patients (black, dashed) is for illustrative purposes

only.

636 **Tables**

637 **Table 1**

638 Clinical and electrographic characteristics of anti-NMDAR encephalitis patients at the time of EEG registration.

Patient (#)	Sex	EEG	Age (years)	Time since diagnosis	Clinical presentation	Sleep EEG structure anomalies
1	f	A^	14.7	≅3mt	Started to speak 2d before EEG, speech problems (single words expressed, slurred pronunciation). Child-like behaviour. Fluctuating confusion, disorientation, agitation. Restlessness. Improving flaccid paresis of the legs (critical illness myopathy, 75d in the intensive care unit)	Severe sleep fragmentation
		B	14.9	≅5 ½mt	Clear clinical improvement compared to EEG A. Increased alertness, speaks more, still slightly blurred and word-finding problems, better motor skills (sitting, walking some steps possible). Behavioral inflexibility	None
2	m	A	7.4	<1mt	The morning before EEG, focal seizure with clonic jerking of the right-side of mouth. Mood swings and slurred speech	None

		B	7.4	<1mt	Clinical improvement compared to EEG A. Slight truncal ataxia (abnormal line gait with closed eyes). Emotional lability. Good visuoconstructive performance. Language impairment (pronunciation, word-finding, speech planning, vowel differentiation, and auditory memory; but normal comprehension), reduced memory capacity and concentration	Period (2.81hrs) of continuous wakefulness after the start of NREM sleep
3	f	A^	4.3	≅1 ½mt	Mutism. Interaction by eye contact preserved. Receptive language better preserved but limited to simple orders. Chorea, allowing walking with assistance and impairing fine motor skills. Neuropsychological testing impossible	Disrupted sleep architecture; frontal seizure patterns
4	f	A	17.9	≅5mt	No abnormalities	None
5*	f	A	20.8	≅63mt after diagnosis, 48mt after relapse	No abnormalities	Period (3.24hrs) of continuous wakefulness after the start of NREM sleep
6	m	A	13.0	≅1 ½mt	mRS 3. Can walk approximately ten steps without support. Starting oral feeding	None

		B	13.0	≅2mt	mRS 3. Better sleep compared to EEG A. Echolalia. Hyperphagia. Intermittent verbal aggressiveness	None
7	f	A	9.5	≅1mt	mRS 2. Speech difficulties (pronunciation and word finding). Fatigue	None
8	f	A^	9.7	≅1mt	Clinically, long sleep episodes. Eats and drinks in drowsiness, orofacial dyskinesia. Muscular hypotonia in extremities. Stable torso. Weak muscle tendon reflexes	Severe sleep fragmentation
9	f	A	13.3	Diagnosis made ≅3mt after EEG (the result of CSF specimen, taken at the time of EEG, received after 3mt)	Started to speak 2d before EEG, speech problems (single words expressed, slurred pronunciation). Child-like behaviour. Fluctuating confusion, disorientation, agitation. Restlessness. Improving flaccid paresis of the legs (critical illness myopathy, 75d in the intensive care unit)	None

An EEG designated 'A' or 'B' indicates whether it concerns the first or, if applicable, the second available recording for the same patient, respectively.

^ EEGs not in the main statistical analysis (see Materials and Methods for details).

* Patient not included in the statistical analysis, but slow wave analysis results assessed individually (see Materials and Methods for details).

d = day(s), hrs = hours, mRS = modified Rankin Scale, mt = month(s), NREM = non-rapid eye movement.

Table 2

Slow wave slope values from (individual) patients with anti-NMDAR encephalitis and controls.

	Slow wave slope (µV/s)		
	Overnight difference (LH - FH)	**FH of NREM sleep**	**LH of NREM sleep**
Patient group (n = 6, mean)	-29.41 (SEM 14.12)*	376.67 (SEM 18.34)**	347.26 (SEM 24.50)
Control group (n = 30, mean)	-78.62 (SEM 7.85)*	444.29 (SEM 10.98)**	365.66 (SEM 6.06)
Patient #1	-10.10	417.44	407.34
Patient #2	-41.74	426.72	385.98
Patient #3	-17.61	297.38	279.78
Patient #4	5.91	418.20	424.11
Patient #5^	-31.57	363.63	332.05
Patient #6	-62.38	361.82	299.44
Patient #7	18.18	330.36	348.54
Patient #8	34.00	307.11	341.09
Patient #9	-64.39	322.50	258.11

*Significant interaction (2x2 mixed ANOVA with a within-subject factor (FH vs. LH) and a between-

subject factor (patients vs. controls), $p < 0.05$)

** Significant difference (two-tailed independent samples *t*-test, $p < 0.05$, Bonferroni corrected for

multiple comparisons by multiplying the *p*-value by the number of tests) between patients and

controls.

^ Not included in statistical analysis, but slow wave analysis results assessed individually (see

Materials and Methods for details)

FH = first hour (of NREM sleep); LH = last hour (of NREM sleep); NREM = non-rapid eye

movement.

Table 3

Further sleep EEG characteristics from patients with anti-NMDAR encephalitis and controls.

	Patients (n = 6)		Controls (n = 30)		*P*-value	
	Slow wave count (#)		**Slow wave count (#)**			
FH of NREM sleep	1976 (1071)		2425 (757)		0.146	
LH of NREM sleep	2099 (513)		2189 (842)		0.770	
Total NREM sleep	10901 (4975)		10153 (4894)		0.544	
	Absolute (hrs)	**Relative (%)**	**Absolute (hrs)**	**Relative (%)**	**Absolute (hrs)**	**Relative (%)**
Sleep period	10.07 (1.54)	N.A.	8.37 (1.48)	N.A.	<0.001*	N.A.
Wake (cont.)	0.21 (0.58)	2.26 (1.83)	0.09 (0.31)	1.11 (4.15)	0.924	0.855
Wake (cum.)	0.64 (1.07)	7.14 (8.81)	0.43 (0.78)	5.49 (7.66)	0.733	0.823
NREM 1	0.43 (1.62)	4.46 (9.14)	0.48 (0.38)	5.57 (4.00)	0.412	0.513
NREM 2/3	5.74 (1.42)	63.62 (27.26)	5.49 (1.37)	69.21 (13.31)	0.667	0.564
REM	2.06 (1.32)	21.39 (8.98)	1.46 (0.84)	18.27 (7.24)	0.627	0.749

Variables are described by median and interquartile range (between parentheses). Two-tailed Mann-

Whitney *U*-tests were used in statistical comparisons between patients and controls.

* Variables significantly different ($p < 0.05$) between patients and controls.

cont. = continuous (longest period); cum. = cumulative; hrs = hours; N.A. = not applicable; NREM =

non-rapid eye movement (sleep); REM = rapid eye movement (sleep); Sleep period = time from the

beginning to the end of sleep (including periods of wakefulness).

Supplementary material

Supplementary Table 1

Additional clinical characteristics of patients with anti-NMDAR encephalitis.

Patient (#)	Sex	Age* (years)	Drug treatment*	Initial presentation of disease (-/+ = before/after EEG)	Cerebral MRI (-/+ = before/after EEG)	Outcome** (time after onset of symptoms)	Additional aspects
1 (A)	f	14.7	Cort, LEV, Bac, LPZ, TBZ, OPZ, Enox, Ca, Mg	Vomiting, behavioral change, confusion, after 2d first seizures, rapid worsening with severe neurological impairment (ventilation), psychotic symptoms, dystonia, choreiform movement disorder, circulation	1st (-2 ½mt) and 2nd (-2 ½mt) no abnormalities 3rd (-½mt) global atrophy (cave: on high dose Cort)	Average cognitive performance, mild to moderate neuropsychological deficits, realizes still improvements in word-finding, no neurological deficits, attending regular school,	
1 (B)		14.9	Cort, LEV, LPZ, TBZ		1st (-5mt) and 2nd (-5mt) no abnormalities 3rd (-3mt) global atrophy (on high dose Cort)		

				support needed (-3mt (A), -5 ½mt (B))		no drugs mentioned (3yr ½mt)	
2 (A)	m	7.4	IVIG, VPA, Pheno (benzo-diazepines some hours before EEG)	Headaches for 5d, then status epilepticus, then fluctuating behavioral changes, emotional lability, agitation, aphasia	1st (-9d) and 2nd (+2d) no abnormalities	No abnormalities, no drugs (2yr 10mt)	
2 (B)		7.4	Cort, LEV, Pheno	and trunk ataxia (-½mt (A), -1mt (B))	1st (-25d) and 2nd (-14d) no abnormalities		
3	f	4.3	RTX pulses	Seizures, then dystonia, agitation and mutism (-1 ½mt)	1st (-1mt), 2nd (+1mt), 3rd (+4mt) no abnormalities	Normal neurological exam, minor executive and attentional deficits (1yr 6mt)	
4	f	17.9	none	Severe psychiatric symptoms only (-5mt)	No abnormalities (-5mt)	No abnormalities, no drugs (9mt)	Ovarian teratoma (removed)
5	f	20.8	none	Somnolence, seizures, confusion (-63mt)	No abnormalities (-5yr 3mt)	No abnormalities, no drugs (0mt)	Relapse $\cong$ 4yr

6 (A)	m	13.0	Cort, 9xPE (until 12d before EEG), Risp, Pheno, FZM, Enox	Behavioral change, epileptic seizures (-1 ½mt (A), -2mt (B))	No abnormalities (-1 ½mt)	Mild learning disability (preexisting), no drugs (3yr 11mt)	Preexisting mild learning disability
6 (B)		13.0	Cort, 9xPE (until 24d before EEG), Pheno, Enox		No abnormalities (-2mt)		
7	f	9.5	Cort, 6xPE (until 10d before EEG), RTX (9d before EEG), Risp, DZM	Paroxysmal episodes, confusion, headache, movement disorder, language disorder (-1 ½mt)	1st no abnormalities (- 1mt) 2nd leptomeningeal enhancement left cerebral hemisphere and in some right frontoparietal, mesial sulci (-½mt)	No abnormalities, no drugs (14mt)	

| 8 | f | 9.7 | GBP, CHD, Clo, melatonin | Confusion, vomiting, diarrhea, uncontrolled movements, visual abnormalities in the right visual field (flashes), dysarthria; then episodes with agitation, emotional instability; then acute word finding troubles and slurred speech, anamnestic problems. Two months after initial symptoms: focal seizures, fluctuating vigilance and mood swings, intermittent agitation, asymmetric muscle tone; then | 1st (-1mt) and 2nd (-2mt) no abnormalities | No abnormalities in daily life, normal neurological exam (14mt), normal cognitive abilities, normal attention, working speed above average, below-average quality of memory of complex figure and copying of complex figure (10mt) | Very first symptoms initially interpreted as confusional migraine |

				dystonia, ataxia, dyskinesia, orofacial dysfunction, cognitive dysfunction, autonomic symptoms, severe sleep disturbance (-2 ½mt)			
9	f	13.3	LZM	Epileptic seizures, increasing speech problems with finally complete motor aphasia, behavioral change (-1mt)	1st no abnormalities (0mt) 2nd no abnormalities (+½mt)	Occasional word-finding difficulties, no abnormalities in neurological examination (4yr, 7mt)	Preexisting language disorder

*at the time of EEG registration. **i.e. clinical features at last follow-up.

An (A) or (B) indicates if the patient data were collected at the time of or before the EEG registered first or second, respectively.

Baclofen (Bac), calcium (Ca), chloralhydrate (CHD), clonidine (Clo), corticosteroids (Cort), d (days), diazepam (DZM), enoxaparin (Enox), flunitrazepam

(FZM), gabapentin (GBP), intravenous immunoglobulins (IVIG), levetiracetam (LEV), levomepromazine (LPZ), lorazepam (LZM), magnesium (Mg), modified

Rankin Scale (mRS), month(s) (mt), omeprazole (OPZ), phenobarbitone (Pheno), plasma exchange (PE), risperidone (Risp), rituximab (RTX), tetrabenazine

(TBZ), valproic acid (VPA), vitamin D (ViDe), year(s) (yr).

Pediatric mRS

mRS 0 No symptoms at all

mRS 1 No significant disabilities despite symptoms in clinical examination; age-appropriate behaviour and further development

mRS 2 Slight disability; unable to carry out all previous activities, but same independence as other age- and sex-matched children (no reduction of levels on the

gross motor function scale)

mRS 3 Moderate disability; requiring some help, but able to walk without assistance; in younger patients, adequate motor development despite mild functional

impairment (reduction of one level on gross motor function scale)

mRS 4 Moderately severe disability; unable to walk without assistance; in younger patients reduction of at least 2 levels on the gross motor function scale

mRS 5 Severe disability; bedridden, requiring constant nursing care and attention

mRS 6 Dead

Data and code availability statement

MATLAB scripts used for the analyses in this study are provided by the corresponding author upon reasonable request.